SCHEMBL13765754

SCHEMBL13765754

Clc1nc(-c2ccc3ccccc3c2)c2nc[nH]c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
MAPK9 P45984 2/20 0.39
MAPK10 P53779 2/20 0.39
MAPK8 P45983 1/20 0.39
HTR2B P41595 1/20 0.37
HTR5A P47898 1/20 0.37
MAOB P27338 1/20 0.37
CYP1A2 P05177 3/20 0.36
KDR P35968 1/20 0.36
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
IDO1 P14902 1/20 0.35
ALDH1A1 P00352 2/20 0.35
AR P10275 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13765758 0.83 KDM4E (0.50) ADORA2AADORA1IDO1ALDH1A1SMN1; SMN2
SCHEMBL14325223 0.81 AHR (0.41) KDRADORA2AADORA1
SCHEMBL13765769 0.80 CYP11B1 (0.38) CYP11B1CYP11B2MAPK9MAPK10MAPK8
SCHEMBL14314227 0.78 PGR (0.44) ALDH1A1KDM4EKMT2A
SCHEMBL14296926 0.77 ADORA3 (0.47) ADORA1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL14325228 0.76 PDPK1 (0.41) IDO1NPC1RAB9AKDM4EMAPT
SCHEMBL13765753 0.74 HSP90AB1 (0.43)
SCHEMBL14316130 0.74 MAPT (0.47) ADORA1ALDH1A1MAPTMEN1KMT2A
SCHEMBL14316012 0.74 PDPK1 (0.38) IDO1MEN1KMT2A
SCHEMBL14249184 0.74 MAPT (0.42) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P CYP11B1 2438/4885CYP11B2 2619/4885MAPK9 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.